Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT: Motixafortide + Pembrolizumab in Pancreatic Cancer
NCT02826486Phase 2Completed
- Sponsor
- BioLineRx Ltd.
- Start
- Sep 2016
- Primary completion
- Sep 2022
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of motixafortide in pancreatic adenocarcinoma (PDAC), sponsored by BioLineRx Ltd.. Started Sep 2016; status: completed.
02
Drugs
motixafortide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02826486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826486.